Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 1874762, 13 pages
http://dx.doi.org/10.1155/2016/1874762
Research Article

Protective Effects of Carvedilol and Vitamin C against Azithromycin-Induced Cardiotoxicity in Rats via Decreasing ROS, IL1-β, and TNF-α Production and Inhibiting NF-κB and Caspase-3 Expression

1Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Elkandarh, Jeddah 21589, Saudi Arabia
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
3Department of Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt

Received 26 December 2015; Revised 27 March 2016; Accepted 12 April 2016

Academic Editor: Antonio Ayala

Copyright © 2016 Nagla A. El-Shitany and Karema El-Desoky. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Food and Drug Administration, FDA Statement Regarding Azithromycin (Zithromax) and the Risk of Cardiovascular Death, Food and Drug Administration, Silver Spring, Md, USA, 2012, http://www.fda.gov/Drugs/ DrugSafety/ucm304372.htm.
  2. P. A. Howard, “Azithromycin-induced proarrhythmia and cardiovascular death,” Annals of Pharmacotherapy, vol. 47, no. 11, pp. 1547–1551, 2013. View at Publisher · View at Google Scholar
  3. N. Matsunaga, Y. Oki, and A. A. Prigollini, “A case of QT-interval prolongation precipitated by azithromycin,” New Zealand Medical Journal, vol. 116, no. 1185, article U666, 2003. View at Google Scholar · View at Scopus
  4. V. Russo, G. Puzio, and N. Siniscalchi, “Azithromycin-induced QT prolongation in elderly patient,” Acta Biomedica, vol. 77, no. 1, pp. 30–32, 2006. View at Google Scholar
  5. B.-H. Huang, C.-H. Wu, C.-P. Hsia, and C. Y. Chen, “Azithromycin-induced torsade de pointes,” Pacing and Clinical Electrophysiology, vol. 30, no. 12, pp. 1579–1582, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Kezerashvili, H. Khattak, A. Barsky, R. Nazari, and J. D. Fisher, “Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors,” Journal of Interventional Cardiac Electrophysiology, vol. 18, no. 3, pp. 243–246, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. J. C. Hancox, M. Hasnain, W. V. Vieweg, E. L. Crouse, and A. Baranchuk, “Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports,” Therapeutic Advances in Infectious Disease, vol. 1, no. 5, pp. 155–165, 2013. View at Publisher · View at Google Scholar
  8. H. Ohara, Y. Nakamura, Y. Watanabe et al., “Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce torsade de pointes,” Cardiovascular Toxicology, vol. 15, no. 3, pp. 232–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Shin, H. Y. Park, and W. J. Koh, “Changes in QT intervals after azithromycin-containing antibiotic therapy in patients with NTM lung disease,” The International Journal of Tuberculosis and Lung Disease, vol. 18, no. 11, pp. 1385–1385, 2014. View at Publisher · View at Google Scholar
  10. T. Yu and T. Niu, “Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency,” Canadian Family Physician, vol. 60, no. 11, pp. 1012–1015, 2014. View at Google Scholar · View at Scopus
  11. Z. K. Lu, J. Yuan, M. Li et al., “Cardiac risks associated with antibiotics: azithromycin and levofloxacin,” Expert Opinion on Drug Safety, vol. 14, no. 2, pp. 295–303, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Samarendra, S. Kumari, S. J. Evans, T. J. Sacchi, and V. Navarro, “QT prolongation associated with azithromycin/amiodarone combination,” Pacing and Clinical Electrophysiology, vol. 24, no. 10, pp. 1572–1574, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Amer, S. Hassan, M. Shariffi, and L. Chueca, “QT interval prolongation associated with azithromycin/methadone combination,” West Indian Medical Journal, vol. 62, no. 8, pp. 864–865, 2013. View at Publisher · View at Google Scholar
  14. A. D. Mosholder, J. Mathew, J. J. Alexander, H. Smith, and S. Nambiar, “Cardiovascular risks with azithromycin and other antibacterial drugs,” The New England Journal of Medicine, vol. 368, no. 18, pp. 1665–1668, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Cocco and P. Jerie, “Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction,” Cardiovascular Toxicology, vol. 15, no. 1, pp. 104–106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Atli, O. S. Ilgin, H. Altuntas, and D. Burukoglu, “Evaluation of azithromycin induced cardiotoxicity in rats,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 3, pp. 3681–3690, 2015. View at Google Scholar · View at Scopus
  17. J. R. Bullinga, R. Alharethi, M. S. Schram, M. R. Bristow, and E. M. Gilbert, “Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure,” Journal of Cardiac Failure, vol. 11, no. 9, pp. 693–699, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. R. E. Shaddy, M. M. Boucek, D. T. Hsu et al., “Carvedilol for children and adolescents with heart failure: a randomized controlled trial,” The Journal of the American Medical Association, vol. 298, no. 10, pp. 1171–1179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. B. Oflaz, S. Balli, A. E. Kibar, I. Ece, C. Akdeniz, and V. Tuzcu, “Effects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathy,” Medical Science Monitor, vol. 19, no. 1, pp. 366–372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Premkumar and C. L. Bowlus, “Ascorbic acid does not increase the oxidative stress induced by dietary iron in C3H mice,” Journal of Nutrition, vol. 134, no. 2, pp. 435–438, 2004. View at Google Scholar · View at Scopus
  21. S. Englard and S. Seifter, “The biochemical functions of ascorbic acid,” Annual Review of Nutrition, vol. 6, pp. 365–406, 1986. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Bednarz, T. Chamiec, and L. Ceremuzyński, “Antioxidant vitamins decrease exercise-induced QT dispersion after myocardial infarction,” Kardiologia Polska, vol. 58, no. 5, pp. 375–379, 2003. View at Google Scholar
  23. Y.-H. Kim, S.-M. Park, M. Kim et al., “Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats,” Toxicology Mechanisms and Methods, vol. 22, no. 6, pp. 488–495, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. H. M. Viswanatha Swamy, U. Wangikar, B. C. Koti, A. H. M. Thippeswamy, P. M. Ronad, and D. V. Manjula, “Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats,” Indian Journal of Pharmacology, vol. 43, no. 5, pp. 507–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. J. Field, W. J. White, and C. M. Lang, “Anaesthetic effects of chloral hydrate, pentobarbitone and urethane in adult male rats,” Laboratory Animals, vol. 27, no. 3, pp. 258–269, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Azhar and H. M. El-Bassossy, “Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance,” PLoS ONE, vol. 9, no. 5, Article ID e98281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Pesce, “Lactate dehydrogenase,” in Methods in Clinical Chemistry, pp. 903–906, 1987. View at Google Scholar
  28. B. Abbot, D. S. Young, and A. Burtis, “Creatine kinase,” in Clinical Chemistry, A. Kaplan, Ed., pp. 1112–1116, The C.V. Mosby, St. Louis, Mo, USA, 1984. View at Google Scholar
  29. M. Uchiyama and M. Mihara, “Determination of malonaldehyde precursor in tissues by thiobarbituric acid test,” Analytical Biochemistry, vol. 86, no. 1, pp. 271–278, 1978. View at Publisher · View at Google Scholar · View at Scopus
  30. G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959. View at Publisher · View at Google Scholar · View at Scopus
  31. M. M. Tarpey, D. A. Wink, and M. B. Grisham, “Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 286, no. 3, pp. R431–R444, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. D. E. Paglia and W. N. Valentine, “Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase,” The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967. View at Google Scholar · View at Scopus
  33. M. Nishikimi, N. Appaji Rao, and K. Yagi, “The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen,” Biochemical and Biophysical Research Communications, vol. 46, no. 2, pp. 849–854, 1972. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Aebi, “Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984. View at Publisher · View at Google Scholar
  35. A. Mazzoleni, M. E. Curtin, R. Wolff, L. Reiner, and G. Somes, “On the relationship between heart weights, fibrosis, and QRS duration,” Journal of Electrocardiology, vol. 8, no. 3, pp. 233–236, 1975. View at Publisher · View at Google Scholar · View at Scopus
  36. A. K. Kela, L. P. Reddy, and D. P. Thombre, “E.C.G. findings in normal rats and after administration of isoproterenol,” Indian Journal of Physiology and Pharmacology, vol. 24, no. 2, pp. 84–90, 1980. View at Google Scholar · View at Scopus
  37. G.-X. Yan and C. Antzelevitch, “Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome,” Circulation, vol. 98, no. 18, pp. 1928–1936, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Liu, B. S. Brown, Y. Wu, C. Antzelevitch, P. R. Kowey, and G.-X. Yan, “Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias,” Heart Rhythm, vol. 3, no. 8, pp. 948–956, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Watanabe, Y. Kobayashi, K. Tanno et al., “Transmural dispersion of repolarization and ventricular tachyarrhythmias,” Journal of Electrocardiology, vol. 37, no. 3, pp. 191–200, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Gupta, C. Patel, H. Patel et al., “T (p-e) /QT ratio as an index of arrhythmogenesis,” Journal Electrocardiology, vol. 41, no. 6, pp. 567–574, 2008. View at Google Scholar
  41. A. Bilginoğlu, D. Aydın, S. Özsoy, and M. D. Hatice Aygün, “Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats,” Türk Kardiyoloji Derneği Arşivi, vol. 42, no. 3, pp. 265–273, 2014. View at Google Scholar
  42. J. Hochrein, F. Sun, K. S. Pieper et al., “Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I Substudy),” The American Journal of Cardiology, vol. 81, no. 9, pp. 1078–1084, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Yilmaz, A. Atessahin, E. Sahna, I. Karahan, and S. Ozer, “Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity,” Toxicology, vol. 218, no. 2-3, pp. 164–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. N. A. El-Shitany, S. El-Haggar, and K. El-desoky, “Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats,” Food and Chemical Toxicology, vol. 46, no. 7, pp. 2422–2428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Salvemini, A. Franzé, A. Iervolino, S. Filosa, S. Salzano, and M. V. Ursini, “Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression,” The Journal of Biological Chemistry, vol. 274, no. 5, pp. 2750–2757, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. W. S. Shin, A. Szuba, and S. G. Rockson, “The role of chemokines in human cardiovascular pathology: enhanced biological insights,” Atherosclerosis, vol. 160, no. 1, pp. 91–102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Cai, W. Lu, Y. Yang, J. Yang, J. Ye, and Z. Gu, “Digitoflavone inhibits IκBα kinase and enhances apoptosis induced by TNF-α through down regulation of expression of nuclear factor κB-regulated gene products in human pancreatic cancer cells,” PLoS ONE, vol. 8, no. 10, Article ID 77126, 2013. View at Google Scholar
  48. T. Rassaf, L. W. Poll, P. Brouzos et al., “Positive effects of nitric oxide on left ventricular function in humans,” European Heart Journal, vol. 27, no. 14, pp. 1699–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Ishiyama, M. Hiroe, T. Nishikawa et al., “Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats,” Circulation, vol. 95, no. 2, pp. 489–496, 1997. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Pacher, R. Schulz, L. Liaudet, and C. Szabó, “Nitrosative stress and pharmacological modulation of heart failure,” Trends in Pharmacological Sciences, vol. 26, no. 6, pp. 302–310, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. B. A. Abdel-Wahaba and M. E. Metwally, “Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-κβ,” Cardiovascular Toxicology, vol. 15, no. 4, pp. 355–365, 2015. View at Google Scholar
  52. A. Yildirir, E. Sade, L. Tokgozoglu, and A. Oto, “The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure,” European Journal of Heart Failure, vol. 3, no. 6, pp. 717–721, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Kawamura, Y. Munetsugu, K. Tanno, and Y. Kobayashi, “Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy,” Journal of Cardiovascular Pharmacology, vol. 61, no. 1, pp. 77–82, 2013. View at Publisher · View at Google Scholar
  54. B. Akdeniz, S. Guneri, I. Z. Savas et al., “Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure,” International Heart Journal, vol. 47, no. 4, pp. 565–573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. C. H. Yadav, M. Akhtar, and R. Khanam, “Isoproterenol toxicity induced ECG alterations in wistar rats: role of histamine H3 receptor agonist imetit,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 5, pp. 654–658, 2014. View at Google Scholar · View at Scopus
  56. B. S. Thippeswamy, S. P. Thakker, S. Tubachi et al., “Cardioprotective effect of Cucumis trigonus roxb on isoproterenol-induced myocardial infarction in rat,” American Journal of Pharmacology and Toxicology, vol. 4, no. 2, pp. 29–37, 2009. View at Publisher · View at Google Scholar
  57. J. S. Patel, S. K. Setty, M. Chakraborty, and J. V. Kamath, “Evaluation of cardioprotective activity of Medohar vati by isoproterenol induced myocardial damage in rats,” International Research Journal of Pharmacy, vol. 3, no. 8, pp. 214–217, 2012. View at Google Scholar
  58. K. Kurosaki, U. Ikeda, Y. Maeda, and K. Shimada, “Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes,” Journal of Molecular and Cellular Cardiology, vol. 32, no. 2, pp. 333–339, 2000. View at Publisher · View at Google Scholar
  59. H. Takano, S. Manchikalapudi, X.-L. Tang et al., “Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits,” Circulation, vol. 98, no. 5, pp. 441–449, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. A. D. Lenarda, G. Sabbadini, L. Salvatore et al., “Long- term effects of carvedilol in idipathic dilated cardioin myopathy with persistent left ventricular dysfunction despite chronic metoprolol,” Journal the College, vol. 33, no. 7, pp. 1926–1934, 1999. View at Google Scholar
  61. M. M. Abdel-Daim, E. W. Ghazy, and M. Fayez, “Synergistic protective role of mirazid (Commiphora molmol) and ascorbic acid against tilmicosin-induced cardiotoxicity in mice,” Canadian Journal of Physiology and Pharmacology, vol. 93, no. 1, pp. 45–51, 2015. View at Publisher · View at Google Scholar
  62. T. Yavuz, I. Altuntas, N. Delibas et al., “Cardiotoxicity in rats induced by methidathion and ameliorating effect of vitamins E and C,” Human and Experimental Toxicology, vol. 23, no. 7, pp. 323–329, 2004. View at Publisher · View at Google Scholar · View at Scopus